Class / Patent application number | Description | Number of patent applications / Date published |
546173000 | Unsaturated carbocyclic ring attached directly to the quinoline ring system by nonionic bonding (e.g., quinophthalones, etc.) | 18 |
20090176987 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION - A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): | 07-09-2009 |
20090270627 | AROMATIC AND AROMATIC/HETEROAROMATIC MOLECULAR STRUCTURES WITH CONTROLLABLE ELECTRON CONDUCTING PROPERTIES - Aromatic and aromatic/heteroaromatic molecular structures with controllable electron conducting properties are derived from the incorporation of electron active substituents in selective positions. | 10-29-2009 |
20090286985 | Benzoxazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Same - An object is to provide a novel benzoxazole derivative. Another object is to reduce driving voltage of a light-emitting element. Still another object is to reduce power consumption of a light-emitting element, a light-emitting device, and an electronic device. A benzoxazole derivative represented by General Formula (G1) is provided. The benzoxazole derivative represented by General Formula (G1) has an electron-injecting property and an electron-transporting property; accordingly, it can be favorably used for a light-emitting element, a light-emitting device, and an electronic device. | 11-19-2009 |
20100004454 | QUINOLINIUM ION DERIVATIVES, PROCESS FOR THE PRODUCTION OF THE DERIVATIVES, PRODUCTS MADE BY USING THE SAME, AND REDUCTION AND OXIDATION METHODS WITH THE DERIVATIVES - An electron donor-acceptor dyad is provided that can provide a charge-separated state with longevity and not only high oxidizing power but also high reducing power. A compound of the present invention is a quinolinium ion derivative represented by the following formula (I), a stereoisomer or tautomer thereof, or a salt thereof: | 01-07-2010 |
20100029945 | Process for the purification of Montelukast - It relates to a process for the purification of Montelukast, or pharmaceutically salts thereof, or solvates thereof, including stereoisomers or mixture thereof which comprises carrying out a specific set of selective solvent extractions of Montelukast or its impurities in a mixture of an organic solvent and water at specific ranges of pH and temperature which depend on the type of impurities to remove. In particular, it comprises at least one wash of an aqueous phase containing crude Montelukast in salt form with an organic solvent, at a pH comprised between 12.0 and 13.5; and optionally one or more washes of the resulting aqueous phase with an organic solvent at a pH comprised between 8.5 and 10.0. Montelukast is recovered by acidification at a pH comprised between 4.5 and 8.0 and solvent extraction, and is isolated either as acid or in salt form. | 02-04-2010 |
20110046380 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND - A method for producing an unsaturated organic compound represented by the formula (3): | 02-24-2011 |
20110082298 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION - A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula ( | 04-07-2011 |
20110207935 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME - The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal plasma uric acid level and the like. The present invention relates to fused ring derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of plasma uric acid level, prodrugs thereof, salts thereof or the like. In the formula (I), X | 08-25-2011 |
20110319624 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION - A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): | 12-29-2011 |
20120016129 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof - Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed. | 01-19-2012 |
20130072688 | METHOD FOR PREPARING AN INTERMEDIATE OF PITAVASTATIN OR OF THE SALT THEREOF - The present invention relates to a method for preparing (4R,6S)-(E)-6-[2-(2-cyclopropyl)-4-(4-fluorophenyl)quinolin-3-yl)-vinyl-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid ester derivative, which is an intermediate of pitavastatin or of the salt thereof, into a crystalline solid form. In addition, the present invention relates to a novel solvate of the intermediate, and to a method for preparing pitavastatin or the salt thereof using the intermediate. | 03-21-2013 |
20130197231 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of formula I: | 08-01-2013 |
20130204000 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION - A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): | 08-08-2013 |
20140005402 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | 01-02-2014 |
20140012004 | NEW PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE - The invention relates to palladium(0) tris{tri-[3,5-bis(trifluoromethyl)-phenyl]-phosphine} complex of formula (I), as well as to its preparation and use. | 01-09-2014 |
20140058109 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION - A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula ( | 02-27-2014 |
20140364614 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM - The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms. | 12-11-2014 |
20160024010 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM - The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms. | 01-28-2016 |